Table 5.
Comparison of clinical characteristics and outcomes of patients with E. coli bacteremia treated with CPZ/SUL with or without 3GC susceptibility
| Characteristic | Cefoperazone susceptibility (mg/L) | ||||
|---|---|---|---|---|---|
| MIC ≤ 16 n = 160 (%) |
MIC > 16 n = 87 (%) |
p value | |||
| Demographics | |||||
| Age, year ± SD | 72.4 | ± 14.1 | 74.1 | ± 12.6 | 0.354 |
| Male, sex | 72 | (45.0) | 52 | (59.8) | 0.027 |
| Comorbidities | |||||
| Heart failure | 13 | (8.1) | 9 | (10.3) | 0.559 |
| Hypertension | 99 | (61.9) | 53 | (60.9) | 0.883 |
| Diabetes mellitus | 67 | (41.9) | 34 | (39.1) | 0.670 |
| Chronic liver diseases | 24 | (15.0) | 16 | (18.4) | 0.490 |
| Chronic kidney diseases | 16 | (10.1) | 17 | (19.8) | 0.035 |
| Peptic ulcer | 13 | (8.1) | 16 | (18.4) | 0.017 |
| Malignancy | 39 | (24.4) | 21 | (24.1) | 0.967 |
| CCI ≥ 3 | 57 | (36.5) | 51 | (60.0) | < 0.001 |
| Clinical severity | |||||
| SOFA score, mean ± SD | 2.14 | ± 2.20 | 3.22 | ± 2.72 | 0.001 |
| Shock | 13 | (8.1) | 8 | (9.2) | 0.773 |
| Pitt bacteremia score ≥ 4 | 4 | (2.5) | 7 | (8.0) | 0.055 |
| Source of bacteremia | 0.002 | ||||
| Primary bacteremia | 40 | (25.0) | 19 | (21.8) | |
| Intra-abdominal | 36 | (22.5) | 3 | (3.4) | |
| Urinary tract | 63 | (39.4) | 51 | (58.6) | |
| Low respiratory tract | 9 | (5.6) | 3 | (3.4) | |
| CRBSI | 1 | (0.6) | 2 | (2.3) | |
| Soft tissue infection | 2 | (1.3) | 2 | (2.3) | |
| Others | 9 | (5.6) | 7 | (8.0) | |
| CPZ/SUL therapy | 0.825 | ||||
| Daily dosage | |||||
| 2 g/2 g | 122 | (76.3) | 67 | (77.0) | |
| 1 g/1 g | 32 | (20.0) | 18 | (20.7) | |
| 0.5 g/0.5 g | 6 | (3.8) | 2 | (2.3) | |
| Duration, days ± SD | 7.8 | ± 3.2 | 8.1 | ± 3.9 | 0.569 |
| Microbiology data | |||||
| CPZ/SUL MIC ≥ 64 mg/L | 0 | (0) | 2 | (2.3) | 0.123 |
| Outcome | |||||
| 30-day mortality | 8 | (5.0) | 3 | (3.4) | 0.751 |
CPZ/SUL cefoperazone/sulbactam, CCI Charlson comorbidity index, CRBSI catheter-related bloodstream infection, SOFA sequential organ failure assessment